PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY END-USER Market segmentation by end-user Comparison by end-user Pharmaceutical and biotechnology companies - Market size and forecast 2018-2023 Research and academic institutes - Market size and forecast 2018-2023 Diagnostic laboratories - Market size and forecast 2018-2023 Hospitals - Market size and forecast 2018-2023 Market opportunity by end-user PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing focus on R&D of new oligonucleotide therapeutics Strategic collaborations and partnerships for oligonucleotide drug discovery and development Rise in demand for low-cost and high-throughput oligonucleotide synthesis PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Agilent Technologies Inc. Danaher Corp. General Electric Co. GenScript Biotech Corp. Kaneka Corp. Merck KGaA Nitto Denko Corp. QIAGEN NV Sarepta Therapeutics Inc. Thermo Fisher Scientific Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global healthcare market Exhibit 03: Segments of global healthcare market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: End-user - Market share 2018-2023 (%) Exhibit 19: Comparison by end-user Exhibit 20: Pharmaceutical and biotechnology companies - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Pharmaceutical and biotechnology companies - Year-over-year growth 2019-2023 (%) Exhibit 22: Research and academic institutes - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Research and academic institutes - Year-over-year growth 2019-2023 (%) Exhibit 24: Diagnostic laboratories - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Diagnostic laboratories - Year-over-year growth 2019-2023 (%) Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Hospitals - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by end-user Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Agilent Technologies Inc. - Vendor overview Exhibit 49: Agilent Technologies Inc. - Business segments Exhibit 50: Agilent Technologies Inc. - Organizational developments Exhibit 51: Agilent Technologies Inc. - Geographic focus Exhibit 52: Agilent Technologies Inc. - Segment focus Exhibit 53: Agilent Technologies Inc. - Key offerings Exhibit 54: Danaher Corp. - Vendor overview Exhibit 55: Danaher Corp. - Business segments Exhibit 56: Danaher Corp. - Organizational developments Exhibit 57: Danaher Corp. - Geographic focus Exhibit 58: Danaher Corp. - Segment focus Exhibit 59: Danaher Corp. - Key offerings Exhibit 60: General Electric Co. - Vendor overview Exhibit 61: General Electric Co. - Business segments Exhibit 62: General Electric Co. - Organizational developments Exhibit 63: General Electric Co. - Geographic focus Exhibit 64: General Electric Co. - Segment focus Exhibit 65: General Electric Co. - Key offerings Exhibit 66: GenScript Biotech Corp. - Vendor overview Exhibit 67: GenScript Biotech Corp. - Business segments Exhibit 68: GenScript Biotech Corp. - Organizational developments Exhibit 69: GenScript Biotech Corp. - Geographic focus Exhibit 70: GenScript Biotech Corp. - Segment focus Exhibit 71: GenScript Biotech Corp. - Key offerings Exhibit 72: Kaneka Corp. - Vendor overview Exhibit 73: Kaneka Corp. - Business segments Exhibit 74: Kaneka Corp. - Organizational developments Exhibit 75: Kaneka Corp. - Geographic focus Exhibit 76: Kaneka Corp. - Segment focus Exhibit 77: Kaneka Corp. - Key offerings Exhibit 78: Merck KGaA - Vendor overview Exhibit 79: Merck KGaA - Business segments Exhibit 80: Merck KGaA - Organizational developments Exhibit 81: Merck KGaA - Geographic focus Exhibit 82: Merck KGaA - Segment focus Exhibit 83: Merck KGaA - Key offerings Exhibit 84: Nitto Denko Corp. - Vendor overview Exhibit 85: Nitto Denko Corp. - Business segments Exhibit 86: Nitto Denko Corp. - Organizational developments Exhibit 87: Nitto Denko Corp. - Geographic focus Exhibit 88: Nitto Denko Corp. - Segment focus Exhibit 89: Nitto Denko Corp. - Key offerings Exhibit 90: QIAGEN NV - Vendor overview Exhibit 91: QIAGEN NV - Product segments Exhibit 92: QIAGEN NV - Organizational developments Exhibit 93: QIAGEN NV - Geographic focus Exhibit 94: QIAGEN NV - Segment focus Exhibit 95: QIAGEN NV - Key offerings Exhibit 96: Sarepta Therapeutics Inc. - Vendor overview Exhibit 97: Sarepta Therapeutics Inc. - Product segments Exhibit 98: Sarepta Therapeutics Inc. - Organizational developments Exhibit 99: Sarepta Therapeutics Inc. - Key offerings Exhibit 100: Thermo Fisher Scientific Inc. - Vendor overview Exhibit 101: Thermo Fisher Scientific Inc. - Business segments Exhibit 102: Thermo Fisher Scientific Inc. - Organizational developments Exhibit 103: Thermo Fisher Scientific Inc. - Geographic focus Exhibit 104: Thermo Fisher Scientific Inc. - Segment focus Exhibit 105: Thermo Fisher Scientific Inc. - Key offerings Exhibit 106: Validation techniques employed for market sizing Exhibit 107: Definition of market positioning of vendors

Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.